Aciex Therapeutics receives US patents for two products.
M2 PHARMA-October 10, 2014-Aciex Therapeutics receives US patents for two products
(C)2014 M2 COMMUNICATIONS
Aciex Therapeutics, a private, US-based ophthalmic development pharmaceutical company, has received a US Patent (No. 8,829,005) covering AC-170 Cetirizine Ophthalmic Compositions and a US Patent (No. 8,765,725) covering AC-155 Fluticasone Propionate Nano-crystalline Compositions from the US Patent and Trademark Office, it was reported yesterday.
US Patent No. 8,829,005 includes method of treatment claims that cover the company's cetirizine product candidate (cetirizine ophthalmic solution, 0.24 percent). US Patent No. 8,765,725 contains both composition of matter and method of uses claims that broadly include Aciex's nanocrystalline formulations of fluticasone propionate.
AC-170 is a formulation of cetirizine (an oral antihistamine, available under brand names including Zyrtec) being assessed for the treatment of allergic conjunctivitis. It is likely to become the first topical application of cetirizine in the eye offered to patients, pending FDA approval.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 10, 2014|
|Previous Article:||RPS Diagnostics secures CE mark for FebriDx POC test.|
|Next Article:||Salix Pharmaceuticals receives approval for UCERIS from FDA.|